News

PharmaEssentia Unveils Promising Phase 3 Results for P1101

PharmaEssentia Unveils Promising Phase 3 Results for P1101

PharmaEssentia Unveils Promising Phase 3 Results for P1101

PharmaEssentia Corporation, a global biopharmaceutical innovator known for its commitment to advancing treatment options in hematology and oncology, has made headlines with its recent positive topline results from the SURPASS-ET clinical trial. This study investigates the innovative drug, ropeginterferon alfa-2b-njft (P1101), specifically designed for treating patients suffering from essential thrombocythemia (ET).

Overview of the SURPASS-ET Clinical Trial

The SURPASS-ET clinical trial is a Phase 3, randomized, open-label study that evaluates the efficacy, safety, and tolerability of P1101 in comparison to anagrelide, a well-known treatment option for ET. The trial enrolled 174 patients who were assigned randomly into two groups; 91 receiving the new treatment and 83 receiving anagrelide. The primary aim was to assess the durability of the response over a 12-month period.

Achievements of the Primary Endpoint

This significant trial met its primary endpoint with impressive results. According to the data, 42.9% of participants in the P1101 group demonstrated durable clinical responses, a stark contrast to only 6.0% in the comparator group. This statistically significant finding (p=0.0001) indicates that P1101 not only achieved its goals but also showcased a favorable safety profile with a lower incidence of treatment-related serious adverse events (TRSAEs).

Exploring Secondary Outcomes

Secondary outcomes further solidified the promise of P1101. The study observed a noteworthy decrease in the JAK2 V617F allelic burden among patients treated with P1101, dropping from 33.7% at the start of the trial to 25.3% after 12 months. In contrast, the anagrelide group showed only a minor reduction, suggesting that P1101 may more effectively address the underlying disease pathology.

Expert Insights on the Results

Ko-Chung Lin, Ph.D., the founder and CEO of PharmaEssentia, expressed great pride in the outcomes of the SURPASS-ET trial. He highlighted that these results represent a potential breakthrough for patients with ET, a rare blood disorder that significantly heightens the risk of serious cardiovascular events. The innovative technology behind P1101, a monopegylated and long-acting interferon, has the potential to change the treatment landscape for ET and similar conditions.

Regulatory Plans and Future Prospects

Looking ahead, PharmaEssentia is preparing to pursue regulatory discussions with the FDA regarding label expansion to include ET for P1101. The company aims to submit the necessary documentation by the end of the upcoming year. They also plan to present detailed clinical trial results, ensuring their findings contribute to the broader medical understanding of ET.

Continued Commitment to Innovation

In addition to the SURPASS-ET study, PharmaEssentia is also engaged in further clinical evaluations of P1101, including the EXCEED-ET clinical trial in North America. This Phase 2b study focuses on the drug's efficacy and safety profile in adult patients with ET, and data is expected to be released mid-next year.

Understanding Essential Thrombocythemia

Essential thrombocythemia is a chronic blood disorder characterized by an overproduction of platelets, often due to genetic mutations. These excessive platelets can cause serious complications such as strokes, heart attacks, and blood clots. This rare condition affects an estimated 148,000 people in the U.S. and presents significant challenges in management.

Advancements with BESREMi

Ropeginterferon alfa-2b-njft is already FDA approved under the brand name BESREMi for polycythemia vera (PV). The company is capitalizing on its established success and plans to extend its use to essential thrombocythemia. BESREMi is notable for its long-acting formulation, allowing for bi-weekly or monthly dosing, tailored to patient needs.

About PharmaEssentia Corporation

Founded in 2003 and headquartered in Taipei, Taiwan, PharmaEssentia has rapidly grown into a key player in the biopharmaceutical sector. The company blends scientific expertise with innovative approaches to develop effective treatments targeting rare diseases and conditions. PharmaEssentia continues to expand its international footprint, with ongoing operations in North America, Japan, and beyond.

Frequently Asked Questions

What is the SURPASS-ET trial?

The SURPASS-ET trial is a Phase 3 clinical study assessing the efficacy and safety of the drug P1101 for treating essential thrombocythemia.

What were the results of the trial?

Results indicated that 42.9% of patients receiving P1101 showed durable clinical responses, significantly higher than the 6% observed in the anagrelide group.

What is essential thrombocythemia (ET)?

Essential thrombocythemia is a rare blood disorder characterized by an overproduction of platelets, increasing the risk of severe cardiovascular events.

What are the future plans for P1101?

PharmaEssentia plans to seek regulatory approval to expand P1101's label to include essential thrombocythemia and continue clinical evaluations.

What is BESREMi?

BESREMi is a long-acting interferon already approved for polycythemia vera, which PharmaEssentia aims to expand for use in essential thrombocythemia.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 59

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Minno Bets on Listener Kids to Build Premium Growth

Updated Category News Views 80

Children’s media rarely gets a clean strategic move, but this one comes pretty close. Minno has signed a worldwide, multi-year agreement making it the exclusive faith-based streaming home for Listener Kids’ video library, while commissioning 66 new episodes for its own service. For a company trying to build a serious Christian family-media business, that is more than...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 89

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
Fayetteville Auction Puts Two Retail Sites Into Play

Updated Category News Views 77

Two lots staring across Sycamore Dairy Road are about to get a public price tag, and that is usually where the real estate story stops being polite. Iron Horse Auction Co. plans to sell a commercial showroom at 3618 Sycamore Dairy Road and a former batting cage facility at 3701 Sycamore Dairy Road through an online-only auction closing Dec. 9 beginning at 2 p.m. They sit...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 104

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 16

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
MemorialCare Adds AI Guardrails for Hidden Aneurysms

Updated Category News Views 31

A brain scan ordered for one reason can suddenly expose a risk nobody knew was sitting there. That is the sober promise behind MemorialCare Neuroscience Institute's rollout of Rapid Aneurysm, an artificial-intelligence tool embedded in qualifying CTA and MRA brain scans across its inpatient and outpatient network. MemorialCare says it is the first health system in Los...

Continue Reading
Dar Global’s $700M Qatar Bet Leans on Trump Branding

Updated Category News Views 29

Luxury property launches rarely arrive quietly, and this one came wrapped in Palm Beach ceremony, championship golf and a very loud brand name. Dar Global has formally introduced Trump International Simaisma, Qatar, a QAR 2.5 billion development—about $700 million—alongside The Trump Organization. That is a meaningful chunk of real estate ambition, not a little side...

Continue Reading

Top 5 Most Recently Viewed Articles

Join SeaStar Medical's CEO for Exciting Insights on Benzinga

Updated Category News Views 157

Join the CEO of SeaStar Medical on Benzinga All Access SeaStar Medical Holding Corporation (Nasdaq: ICU), recognized for its innovative approach in the healthcare sector, is proud to announce an exciting event featuring its CEO, Eric Schlorff. The event, scheduled for today, promises to be a significant moment for those interested in advancements in treatments for...

Continue Reading
E-Commerce Fuels Surge in Europe's Logistics Market Growth

Updated Category News Views 220

Surge in Europe's Logistics Market Driven by E-Commerce The logistics market in Europe is poised for remarkable growth, projected to expand by approximately USD 48.4 billion between 2025 and 2029. This growth trajectory, which reflects a compound annual growth rate (CAGR) of 3.4%, is predominantly fueled by the booming e-commerce sector. As consumer behaviors shift to...

Continue Reading
Procept Bio's 18% Dive: Unpacking Fraud Allegations

Updated Category News Views 64

Procept's Plunge: Not Your Average Market Tumble When a stock takes an 18% nosedive, it’s like ringing alarm bells down Wall Street. That’s exactly what happened with Procept BioRobotics Corporation (NASDAQ:PRCT), when it found itself knee-deep in controversies over alleged shady financial practices. The Allegations: Inflated Sales and Bulk Orders Procept allegedly...

Continue Reading
Key Outcomes from AB Akola Group's Latest Shareholder Meeting

Updated Category News Views 219

AB Akola Group's Extraordinary General Meeting Insights The Extraordinary General Meeting of AB Akola Group brought together shareholders to discuss various important agendas concerning the company's future. With a total shareholding of 167,170,481 shares, of which 166,566,819 held voting rights, the company witnessed an engaging assembly of its stakeholders. Major...

Continue Reading
GO Residential REIT Secures New Financing for Growth and Flexibility

Updated Category News Views 230

Enhancing Financial Stability: GO Residential REIT's New Financing GO Residential Real Estate Investment Trust (REIT) is thrilled to announce the successful refinancing of its prestigious property, One East River Place. This strategic move is designed to unlock significant liquidity and enhance the REIT's financial flexibility. The refinancing involves a new five-year...

Continue Reading